Oral Sumatriptan for Acute Treatment of Migraine A Single-blind ?Placebo-controlled Study

J Korean Neurol Assoc > Volume 13(1); 1995 > Article

Journal of the Korean Neurological Association 1995;13(1): 77-83.

급성 편두통에 대한 경구용 Sumatriptan의 단일맹검, Placebo ?대조연구

조광덕, 이명종

울산대학교 서울중앙병원 신경과

Oral Sumatriptan for Acute Treatment of Migraine A Single-blind ?Placebo-controlled Study

Kwang Deog Jo, M.D., Myoung Chong Lee, M.D.

Department of Neurology, Asan Medical Center, University of Ulsan

Abstract

The efficacy and safety of oral sumatriptan as a 100mg conventional tablet was evaluated in the acute treatment of migrame in a single-blind, randomized, placebocontrolled, parallel-group study. Thirty patients were assigned to the sumatriptan group And other 30 to placebo group. Each patient was treated a total of three attacks. Patients recorded details of each attack and response to treatment on a diary card. Sumatriptan was significantly more effective than placebo in relieving headache(moderate/severe reduced to mild/none) at 4 hr(67.2 vs 15.4%; P< 0.001). Overall therapeutic effect of sumatriptan was excellent(89.6 vs 23%; P< 0.001). Compared with placebo, more patients on sumatriptan were pain7free by 2 hr(33.6 vs 0%; P< 0. 001) and 4 hr (25.7 vs 2. 0%; P( 0. 001). The proportion of patients who required rescue medication was significantly (P< 0. 001) lower 'in the sumatriptan group when compared with the placebo group(2.4 vs 21%). The overall incidence of patients reporting a dverse events was 39% in sumatriptan group and 10% in placebo (P= 0. 005). The most commonly reported events in the sumatriptan-treated patients were nausea and/or vomiting, chest discomfort, general weakness, tightness of head; these were however generally mild, transient and tolerable. It is concluded that oral sumatriptan is an effective, well-tolerated prompt remedy for acute attacks of migraine.